Alzheimer's disease (AD) represents a degenerative nerve disease that highly occurs in older people who grow fast across developing countries. A precarious target in the controlling of AD aims at boosting presently accessible pharmacologic therapies' impacts, e.g., CDP-Choline. Citicoline (CT) denotes a food complement utilized as a manager with neuroprotection characteristics for neurological disarrays (including stroke, brain injury, AD, and dementia). CT assistances as an intermedial component in phospholipid uptake and improves neuronal cell membranes' consistency. Companies chiefly market most approved drugs for controlling AD as traditional medicines taken via the mouth. Because of the gastrointestinal drawbacks and failure to target the brain, such medications, and dosage regimens obstruct patient obedience and cause stoppage of the treatments.
Nanotechnology-based drug delivery systems (DDS) controlled in various ways are favorable tools in enhancing the compliance of patients and succeeding in improved treatment results. The literature article was searched in the National Center for Biotechnology Information Advances Science and Health (NCBI), Wiley online library, and Science Direct database utilizing the keywords Alzheimer's disease, Citicoline, and nanotechnology. Articles that appeared appropriate based on title and abstract were included. Also, an individual collection of literature reviews on the therapeutic effects of CT and the lipid-based vesicular system was referred. This article review discusses AD, pathogenesis, therapeutic objectives and treatments, CT therapeutic effect in AD and other central disorders, the nanosizing lipid-based vesicles, and advantages in brain targeting.